Want to see BRTX full AI Analyst Report?
Total Valuation
BioRestorative Therapies has a market cap or net worth of $10.19M. The enterprise value is $514.34K.
Market Cap$10.19M
Enterprise Value$514.34K
Share Statistics
BioRestorative Therapies has 25,478,170 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding25,478,170
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
BioRestorative Therapies’s return on equity (ROE) is -39.92 and return on invested capital (ROIC) is -4386.10%.
Return on Equity (ROE)-39.92
Return on Assets (ROA)-3.49
Return on Invested Capital (ROIC)-4386.10%
Return on Capital Employed (ROCE)-43.86
Revenue Per Employee32.70K
Profits Per Employee-1.29M
Employee Count11
Asset Turnover0.09
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of BioRestorative Therapies is ―. BioRestorative Therapies’s PEG ratio is -0.02.
PE Ratio―
PS Ratio29.50
PB Ratio29.75
Price to Fair Value29.75
Price to FCF-0.97
Price to Operating Cash Flow-0.30
PEG Ratio-0.02
Income Statement
In the last 12 months, BioRestorative Therapies had revenue of 359.70K and earned -14.24M in profits. Earnings per share was -1.58.
Revenue359.70K
Gross Profit335.86K
Operating Income-15.65M
Pretax Income-14.24M
Net Income-14.24M
EBITDA-14.03M
Earnings Per Share (EPS)-1.58
Cash Flow
In the last 12 months, operating cash flow was -11.82M and capital expenditures -79.67K, giving a free cash flow of -11.90M billion.
Operating Cash Flow-11.82M
Free Cash Flow-11.90M
Free Cash Flow per Share-0.47
Dividends & Yields
BioRestorative Therapies pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.26
52-Week Price Change-74.19%
50-Day Moving Average0.31
200-Day Moving Average0.80
Relative Strength Index (RSI)56.83
Average Volume (3m)20.75M
Important Dates
BioRestorative Therapies upcoming earnings date is Aug 18, 2026, After Close (Confirmed).
Last Earnings DateMay 20, 2026
Next Earnings DateAug 18, 2026
Ex-Dividend Date―
Financial Position
BioRestorative Therapies as a current ratio of 0.84, with Debt / Equity ratio of 1.14%
Current Ratio0.84
Quick Ratio0.84
Debt to Market Cap0.00
Net Debt to EBITDA0.11
Interest Coverage Ratio0.00
Taxes
In the past 12 months, BioRestorative Therapies has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
BioRestorative Therapies EV to EBITDA ratio is -0.65, with an EV/FCF ratio of -0.83.
EV to Sales25.30
EV to EBITDA-0.65
EV to Free Cash Flow-0.83
EV to Operating Cash Flow-0.84
Balance Sheet
BioRestorative Therapies has $3.59M in cash and marketable securities with $34.52K in debt, giving a net cash position of $3.56M billion.
Cash & Marketable Securities$3.59M
Total Debt$34.52K
Net Cash$3.56M
Net Cash Per Share$0.14
Tangible Book Value Per Share-$0.02
Margins
Gross margin is 92.09%, with operating margin of -4350.05%, and net profit margin of -3959.40%.
Gross Margin92.09%
Operating Margin-4350.05%
Pretax Margin-3959.40%
Net Profit Margin-3959.40%
EBITDA Margin-3901.03%
EBIT Margin-3959.40%
Analyst Forecast
The average price target for BioRestorative Therapies is $1.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$1.00
Price Target Upside-15.25% Downside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast-8.47%
EPS Growth Forecast25.61%